Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
Compugen (NASDAQ: CGEN) will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen (NASDAQ: CGEN) will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.
Telephone access is available in the U.S. and internationally, and a replay will be posted on the company website after the live webcast.
Details
News Market Reaction – CGEN
On Feb 17, the day this news came out, CGEN closed 1.82% above the previous close.
Data tracked by StockTitan Argus for the Feb 17 session.
Key Figures
- Upfront royalty payment
- $65 million
- Rilvegostomig royalty monetization deal, 2025-12-17
- Milestone payment
- $25 million
- Additional milestone tied to next BLA acceptance
- Potential milestones
- $195 million
- Total potential regulatory and commercial milestones for partnerships
- Q3 2025 cash
- $86.1M
- Cash balance with runway into Q3 2027
- Q3 2025 revenue
- $1.9M
- Compared with $17.1M in prior-year quarter
- Q3 2025 net loss
- $6.98M
- Loss of $0.07 per share after prior-quarter profit
- Median PFS
- 10.5 months
- Pooled Phase 1 COM701 patients deriving clinical benefit
- Earnings call time
- 8:30 AM ET
- Q4 and full-year 2025 results call on March 2, 2026
Historical Context
-
New independent director with extensive biotech and healthcare strategy experience added.
-
Non-dilutive monetization of rilvegostomig royalties with upfront and milestone payments.
-
Q3 2025 financials, cash runway, clinical data and partnership updates reported.
-
Participation in Stifel 2025 Healthcare Conference with investor webcast access.
-
Announcement of timing and access details for Q3 2025 results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link.
Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company Contact:
Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2025-results-on-monday-march-2-2026-302689329.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.